PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference - News Summed Up

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference


Preliminary 2023 unaudited financial results and 2024 financial guidance will also be provided. Unaudited 2023 Financial Results:Total unaudited net revenue for full-year 2023 was approximately $946 million. 2024 Financial Guidance:PTC anticipates total revenues for the full-year 2024 to be between $600 million and $850 million. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi or Waylivra.


Source: The Bubble January 09, 2024 00:53 UTC



Loading...
Loading...
  

Loading...